Poghni Allen Peri‐Okonny

Poghni Allen Peri‐Okonny

Auto-generated profile, based on publicly available information

Poghni Allen Peri‐Okonny

Winchester Cardiology and Vascular Medicine, Winchester Medical Center, Winchester, Virginia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in JACC: Heart Failure
Verified
Journal Article
Closed access
PPPoghni A. Peri-Okonny
Poghni A. Peri-Okonny
XMXiaojuan Mi
Xiaojuan Mi
YKYevgeniy Khariton
Yevgeniy Khariton
KPKrishna K. Patel
Krishna K. Patel
LTLaine Thomas
Laine Thomas
JSJohn A. Spertus
John A. Spertus

13 April 2022 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
KPKrishna K. Patel
Krishna K. Patel
PPPoghni A. Peri-Okonny
Poghni A. Peri-Okonny
RQRaed Qarajeh
Raed Qarajeh
FPFemina S. Patel
Femina S. Patel
BSBrett W. Sperry
Brett W. Sperry
TBTimothy M. Bateman
Timothy M. Bateman
Background: Coronary artery calcium score (CACS) is an anatomic measure of calcified atherosclerosis. Myocardial perfusion defects and reduced myocardial blood flow reserve (MBFR) are physiological measures of ischemia and coronary circulatory health. We aimed to assess the relative prognostic importance of MBFR, perfusion defects, and CACS in patients with suspected coronary artery disease. Methods: A total of 5983 consecutive patients without known history of coronary artery disease or cardiomyopathy, who underwent a CACS and 82 Rb positron emission tomography myocardial perfusion imaging between 2010 and 2016, were followed for all-cause death (n=785) over median of 3 years. Prognostic value was assessed using multivariable Cox regression models, and incremental risk discrimination for imaging variables was evaluated by comparing model c-indices after adjusting for clinical risk factors (RF). Results: Mean age was 67.1 years, 60% were female, and 83% were symptomatic. CACS was 0 in 22%, abnormal perfusion in 19%, and MBFR <2 in 53.3%. When added to RF, the model with MBFR had the best fit (c=0.78, P <0.0001). Addition of CACS to model with RF and perfusion (c=0.77) offered modest improvement in discrimination over the model with RF and perfusion (c=0.76, P =0.02). Adding CACS to a model with RF, perfusion, and MBFR did not provide incremental prognostic value (c=0.785 for both, P =0.16). CACS and MBFR both had independent prognostic value in patients with normal and abnormal myocardial perfusion imaging. Even among patients with CACS of 0, MBFR <2 was present in 37.8%, being associated with higher risk of death (hazard ratio per 0.1↓, 1.10 [1.04–1.15]; P <0.001), but perfusion defects were not. Conclusions: Use of anatomic testing such as CACS of 0 to avoid myocardial perfusion imaging in symptomatic patients could lead to missing microvascular dysfunction in 4 out of 10 patients, a finding associated with a high mortality risk. Higher CACS was independently associated with the risk of death but did not provide incremental prognostic value over positron emission tomography with MBFR.

1 September 2018 in JACC
Verified
Journal Article
Closed access
PPPoghni A. Peri-Okonny
Poghni A. Peri-Okonny
KPKrishna K. Patel
Krishna K. Patel
PJPhilip G. Jones
Philip G. Jones
TBTracie Breeding
Tracie Breeding
KGKensey L. Gosch
Kensey L. Gosch
SASuzanne V. Arnold
Suzanne V. Arnold

16 April 2019 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
PPPoghni A. Peri‐Okonny
Poghni A. Peri‐Okonny
YLYangbo Liu
Yangbo Liu
SMS. Chris Malaisrie
S. Chris Malaisrie
CHChetan P. Huded
Chetan P. Huded
SKSamir Kapadia
Samir Kapadia
SASuzanne V. Arnold
Suzanne V. Arnold
Background: Statins may reduce mortality after transcatheter aortic valve replacement (TAVR) through prevention of atherosclerotic events or pleiotropic effects. However, the competing mortality risks in TAVR patients may dilute any positive effect of statins. We sought to understand the association of statin use with post‐TAVR mortality. Methods and Results: We included high– or intermediate–surgical risk patients who underwent TAVR as a part of the PARTNER (Placement of Aortic Transcatheter Valves) II and Sapien 3 trials and registries. Outcomes included 2‐year all‐cause, cardiovascular, and noncardiovascular mortality. We used propensity score matching to generate matched pairs between those discharged on a statin and those not on a statin after TAVR. Bias was explored with falsification end points (urinary infection, hip fracture). Among 3956 patients who underwent TAVR, we matched 626 patients on a statin with 626 patients not on a statin at discharge. Among matched patients, statin use was associated with lower risk of all‐cause (hazard ratio [HR] 0.65, 95% CI 0.49‐0.87, P =0.001), cardiovascular (HR 0.66, 95% CI 0.46‐0.96, P =0.030), and noncardiovascular mortality (HR 0.64, 95% CI 0.44‐0.99, P =0.045) compared with no statin use. The survival curves diverged within 3 months and continued to separate over a median follow‐up of 2.1 years. The falsification end points were similar among groups (urinary infection, P =0.66; hip fracture, P =0.64). Conclusions: In an observational, propensity‐matched analysis of TAVR patients, statin use was associated with lower rates of cardiovascular and noncardiovascular mortality compared with no statin use. Given the early emergence of the apparent protective effect of statins, this result may be driven either by pleiotropic effects or by residual confounding despite propensity‐matching methodology.

19 May 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
VHVittal Hejjaji
Vittal Hejjaji
AMAli O Malik
Ali O Malik
PPPoghni A Peri-Okonny
Poghni A Peri-Okonny
MTMerrill Thomas
Merrill Thomas
YTYuanyuan Tang
Yuanyuan Tang
PCPaul S Chan
Paul S Chan
Background: Effective and timely delivery of cardiac arrest interventions during in-hospital cardiac arrest resuscitation is associated with greater survival. Whether a mobile app that provides timely reminders of critical interventions improves adherence to Advanced Cardiovascular Life Support (ACLS) guidelines among house officers, who may lack experience in leading resuscitations, remains unknown. Objective: The aim of this study was to assess the impact of a commercially available, dynamic mobile app on house officers’ adherence to ACLS guidelines. Methods: As part of a quality improvement initiative, internal medicine house officers were invited to participate and randomized to lead 2 consecutive cardiac arrest simulations, one with a novel mobile app and one without a novel mobile app. All simulations included 4 cycles of cardiopulmonary resuscitation with different cardiac arrest rhythms and were video recorded. The coprimary end points were chest compression fraction and number of correct interventions in each simulation. The secondary end point was incorrect interventions, defined as interventions not indicated by the 2015 ACLS guidelines. Paired t tests compared performance with and without the mobile app. Results: Among 53 house officers, 26 house officers were randomized to lead the first simulation with the mobile app, and 27 house officers were randomized to do so without the app. Use of the mobile app was associated with a higher number of correct ACLS interventions (out of 7; mean 6.2 vs 5.1; absolute difference 1.1 [95% CI 0.6 to 1.6]; P<.001) as well as fewer incorrect ACLS interventions (mean 0.3 vs 1.0; absolute difference –0.7 [95% CI –0.3 to –1.0]; P<.001). Simulations with the mobile app also had a marginally higher chest compression fraction (mean 90.9% vs 89.0%; absolute difference 1.9% [95% CI 0.6% to 3.4%]; P=.007). Conclusions: This proof-of-concept study suggests that this novel mobile app may improve adherence to ACLS protocols, but its effectiveness on survival in real-world resuscitations remains unknown.

19 October 2021 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
MTMerrill Thomas
Merrill Thomas
BSBrett W. Sperry
Brett W. Sperry
PPPoghni Peri-Okonny
Poghni Peri-Okonny
AMAli O. Malik
Ali O. Malik
AMA. Iain McGhie
A. Iain McGhie
KPKrishna K. Patel
Krishna K. Patel
Background: Rubidium-82 positron emission tomography myocardial perfusion imaging provides measurements of perfusion, myocardial blood flow and reserve (MBFR), and changes in left ventricular ejection fraction (LVEF) at rest and peak stress. Although all of these variables are known to provide prognostic information, they have not been well studied in patients with heart failure due to reduced LVEF. Methods: Between 2010 and 2016, 1255 consecutive unique patients with LVEF≤40% were included in this study who underwent rubidium-82 positron emission tomography myocardial perfusion imaging and did not have subsequent revascularization within 90 days. Perfusion assessment was scored semiquantitatively, and LVEF reserve (stress-rest LVEF) and global MBFR (stress/rest MBF) were quantified using automated software. Cox proportional hazards models adjusted for 14 clinical and 7 test characteristics were used to define the independent prognostic significance of MBFR on all-cause mortality. Results: Of 1255 patients followed for a mean of 3.2 years, 454 (36.2%) died. After adjusting for clinical variables, the magnitude of fixed and reversible perfusion defects was prognostic of death ( P =0.02 and 0.01, respectively), while the rest LVEF was not ( P =0.18). The addition of LVEF reserve did not add any incremental value, while the addition of MBFR revealed incremental prognostic value (hazard ratio per 0.1 unit decrease in MBFR=1.08 [95% CI, 1.05–1.11], P <0.001) with fixed and reversible defects becoming nonsignificant ( P =0.07 and 0.29, respectively). There was no interaction between MBFR and cause of cardiomyopathy (ischemic versus nonischemic). Conclusions: In patients with a known cardiomyopathy who did not require early revascularization, reduced MBFR as obtained by positron emission tomography myocardial perfusion imaging is associated with all-cause mortality while other positron emission tomography myocardial perfusion imaging measures were not.